Polymorphism of the CD30 promoter microsatellite repressive element is associated with development of primary cutaneous lymphoproliferative disorders

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 5, 2005, Pages 1322-1325

  Franchina, Maria ^a,b   Kadin, Marshall E ^c   Abraham, Lawrence J ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN; TUMOR NECROSIS FACTOR RECEPTOR;

ALLELE; ARTICLE; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DNA POLYMORPHISM; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HYPOTHESIS; LARGE CELL LYMPHOMA; LYMPHOID CELL; LYMPHOMATOID PAPULOSIS; LYMPHOPROLIFERATIVE DISEASE; MALE; PATHOGENESIS; PRIMARY CUTANEOUS LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROMOTER MICROSATELLITE REPRESSIVE ELEMENT; PROMOTER REGION; PROTEIN FAMILY; SIGNAL TRANSDUCTION;

ANTIGENS, CD30; BOSTON; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LYMPHOMA, LARGE-CELL; LYMPHOMATOID PAPULOSIS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MICROSATELLITE REPEATS; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); TRANSCRIPTION, GENETIC;

EID: 18544383148     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-04-0826     Document Type: Article

References (17)

1. Willemze R, Beljaards RC. The spectrum of primary cutaneous CD30(Ki-1)-positive lymphoproliferative disorders. A proposal for classification and guidelines for the management and treatment. J Am Acad Dermatol 1993;28:973.
2. Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the cutaneous lymhoma study group of the European organisation for research and treatment of cancer. Bood 1997;90:354-71.
3. Macaulay WL. Lymphomatoid papulosis. A continuing self-healing-eruption, clinically benign-histologically malignant. Arch Dermatol 1968;97:23-30.
4. El Shabrawi-Caelen L, Kerl H, Cerroni L. Lymphomatoid papulosis: reappraisal of clinicopathologic presentation and classification into subtypes A, B, and C. Arch Dermatol 2004;40:441-7.
5. Beljaards RC, Willemze R. The prognosis of patients with lymphomatoid papulosis associated with malignant lymphomas. Br J Dermatol 1992;126:596-602.
6. Sanchez NP, Pittelkow MR, Muller SA, Banks PM, Winkelmann RK. The clinicopathologic spectrum of lymphomatoid papulosis: a study of 31 cases. J Am Acad Dermatol 1983;8:81-94.
7. Christensen HK, Thomsen K, Vejlsgaard GL. Lymphomatoid papulosis: a follow-up study of 41 patients. Semin Dermatol 1994;13:197-201.
8. Cabanillas F, Armitage J, Pugh WC, Weisenburger D, Duvic M. Lymphomatoid papulosis: a T cell dyscarsia with a propensity to transform into malignant lymphoma. Ann Intern Med 1995;122:210-7.
9. Paulli M, Berti E, Rosso R, et al. CD30/Ki-1 positive lymphoproliferative disorders of the skin-clinicopathologic correlation and statistical analysis of 86 cases: a mulicentric study from the European organization for research and treatment of cancer. Cutaneous Lymphoma Project Group. J Clin Oncol 1995;13:1343-54.
10. Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30+ lymphoproliferative disorders: a report from the Dutch cutaneous lymphoma group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000;95:3653-61.
11. Kaudewitz P, Stein H, Plewig G, et al. Hodgkin's disease followed by lymphomatoid papulosis. Immunophenotypic evidence for a close relationship between lymphomatoid papulosis and Hodgkin's disease. J Am Acad Dermatol 1990;22:999-1006.
12. Harrington DS, Braddock SW, Blocher KS, Weisenburger DD, Sanger W, Armitage JO. Lymphomatoid papulosis and progression to T cell lymphoma: an immunophenotypic and genotypic an analysis. J Am Acad Dermatol 1989;21:951-7.
13. Wang HH, Meyers T, Lach LJ, Hseih CC, Kadin ME. Increased risk of lymphoid and non-lymphoid malignancies in patients with lymphomatoid papulosis. Cancer 1999;86:1240-5.
14. Chott A, Vonderheid EC, Olbricht S, Miao NN, Balk SP, Kadin ME. The same dominant T cell clone is present in multiple regressing skin lesions and associated T cell lymphomas of patients with lymphomatoid papulosis. J Invest Dermatol 1996;106:696-700.
15. Levi E, Wang Z, Petrogiannis-Haliotis T, et al. Distinct effects of CD30 and Fas signalling in cutaneous anaplastic lymphomas: a possible mechanism for disease progression. J Invest Dermatol 2000;115:1034-40.
16. Croager EJ, Gout AM, Abraham LJ. Involvement of Sp1 and microsatellite represser sequences in the transcriptional control of the human CD30 gene. Am J Path 2000;156:1723-31.
17. McIntyre MQ, Price P, Franchina M, French MA, Abraham LJ. Distribution of human CD30 gene promoter microsatellite alleles in healthy and human immunodeficiency virus-1 infected populations. Eur J Immunogenet 2003;30:125-8.